FDA approves Klygefa gefurulimab for adults with AChR-positive generalised myasthenia gravis

The FDA has approved Klygefa, a weekly subcutaneous complement inhibitor, for adults with acetylcholine receptor antibody-positive generalised myasthenia gravis, adding another targeted treatment option for this autoimmune neuromuscular disorder.
The US Food and Drug Administration approved Klygefa (gefurulimab-gaks) on 13 November 2026 for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis, authorising a complement-inhibiting therapy administered by subcutaneous injection with an initial loading dose followed by weekly maintenance dosing.
The medicine carries a boxed warning for serious meningococcal infections and is subject to a restricted Risk Evaluation and Mitigation Strategy, reflecting the infection risks associated with complement inhibition; the approval applies to the specified antibody-positive adult population and is a new medicine authorisation rather than an orphan-drug designation or approval for all myasthenia gravis subtypes.
Field | Content |
Article Type | Approvals |
Product Brand Name | Klygefa |
Active Ingredient | Gefurulimab-gaks |
Drug Classification | Complement inhibitor |
Regulatory Authority | US Food and Drug Administration |
Approval Date | 13 November 2026 |
Regulatory Decision | New medicine approval |
Geographic Scope | United States |
Therapeutic Area | Neurology |
Disease | Generalised myasthenia gravis |
Disease Abbreviation | gMG |
Approved Population | Adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis |
Required Antibody Status | Anti-acetylcholine receptor antibody-positive |
Antibody Abbreviation | AChR |
Administration Route | Subcutaneous injection |
Initial Dosing | Loading dose |
Maintenance Dosing | Weekly |
Therapeutic Mechanism | Complement inhibition |
Boxed Warning | Serious meningococcal infections |
Risk Management Requirement | Restricted Risk Evaluation and Mitigation Strategy |
Risk Management Abbreviation | REMS |
Infection Safety Concern | Meningococcal infection risk associated with complement inhibition |
Approved for All Myasthenia Gravis Subtypes | No |
Orphan-Drug Designation Only | No |
Regulatory Status | FDA-approved medicine |
What Happened | The FDA approved Klygefa for adults with AChR antibody-positive generalised myasthenia gravis. |
Why It Matters | The authorisation expands the range of targeted treatment options for eligible adults with this autoimmune neuromuscular disease. |
Clinical Significance | The medicine provides a subcutaneous complement-inhibiting treatment option with weekly maintenance administration. |
Regulatory Significance | Represents a new FDA medicine approval for a defined antibody-positive myasthenia gravis population. |
Safety Significance | The boxed warning and restricted REMS reflect the potentially serious consequences of meningococcal infection. |
Population Clarification | The approved indication is limited to adults with AChR antibody-positive generalised disease. |
Key Takeaway | Klygefa has received FDA approval for AChR-positive generalised myasthenia gravis in adults, subject to significant infection-related precautions. |
What to Watch | Commercial availability, clinical adoption, treatment access, vaccination and risk-management implementation, and real-world safety. |
Primary Source | US Food and Drug Administration |
Primary Source URL | https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 |
Submitted Source | NeurologyLive |
Submitted Source URL | https://www.neurologylive.com/view/fda-approves-gefurulimab-generalized-myasthenia-gravis |
Relevant Date | 13 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments